Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor

JAMA Psychiatry

Volumn 70, Issue 12, 2013, Pages 1267-1275

  Lane, Hsien Yuan ^b,c   Lin, Ching Hua ^d   Green, Michael F ^e,f   Hellemann, Gerhard ^e   Huang, Chih Chia ^b,c   Chen, Po Wei ^g   Tun, Rene ^a   Chang, Yue Cung ^h   Tsai, Guochuan E ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d Kaohsiung Municipal Kai Syuan Psychiatric Hospital   (Taiwan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^g Department of Psychiatry   (Taiwan)

^h TAMKANG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BENZOIC ACID; CHLORPROMAZINE; DEXTRO AMINO ACID OXIDASE; FLUPENTIXOL; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADD ON THERAPY; ADULT; AGED; ALERTNESS; ARTICLE; BARNES AKATHISIA SCALE; BLOOD CELL COUNT; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EMOTIONAL INTELLIGENCE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HAMILTON SCALE; HUMAN; INSOMNIA; LEARNING; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROBLEM SOLVING; QUALITY OF LIFE; QUALITY OF LIFE SCALE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL COGNITION; TACHYCARDIA; TAIWAN; THINKING; TREATMENT DURATION; WECHSLER INTELLIGENCE SCALE; WEIGHT GAIN; WORKING MEMORY;

EID: 84890018607     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.2159     Document Type: Article

References (71)

1. Malla A, Payne J. First-episode psychosis. Schizophr Bull. 2005;31(3):650-671.
2. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58(1):24-32.
3. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153(3):321-330.
4. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
5. Abbott A. Schizophrenia: the drug deadlock. Nature. 2010;468(7321):158- 159.
6. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry. 1994;51(3):199-214.
7. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002;42:165-179.
8. Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav. 2012;100(4):665-677.
9. Brisch R, Bernstein HG, Krell D, et al. Dopamine-glutamate abnormalities in the frontal cortex associated with the catechol-Omethyltransferase (COMT) in schizophrenia. Brain Res. 2009;1269:166-175.
10. Rosse RB, Theut SK, Banay-SchwartzM, et al. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia. Clin Neuropharmacol. 1989;12(5):416-424.
11. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16(5):522-537.
12. Tsai G, Lane HY, Yang P, ChongMY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004;55(5):452-456.
13. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia. Arch Gen Psychiatry. 2005;62(11):1196-1204.
14. Lane HY, Huang CL, Wu PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006;60(6):645-649.
15. Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia. Biol Psychiatry. 2008;63(1):9-12.
16. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13(4):451-460.
17. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998;44(11):1081-1089.
18. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593-1602.
19. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatmentrefractory schizophrenia. Biol Psychiatry. 2005;57(6):577-585.
20. ScolariMJ, Acosta GB. D-serine: a new word in the glutamatergic neuro-glial language. Amino Acids. 2007;33(4):563-574.
21. Snyder SH. Molecules of madness. Cell. 2009;139(7):1212-1215.
22. Nishikawa T. Analysis of free D-serine in mammals and its biological relevance. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(29):3169- 3183.
23. Fukui K, Miyake Y. Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase. J Biol Chem. 1992;267(26):18631-18638.
24. Vanoni MA, Cosma A, Mazzeo D, Mattevi A, Todone F, Curti B. Limited proteolysis and x-ray crystallography reveal the origin of substrate specificity and of the rate-limiting product release during oxidation of D-amino acids catalyzed by mammalian D-amino acid oxidase. Biochemistry. 1997;36(19):5624- 5632.
25. Sasabe J, Miyoshi Y, Suzuki M, et al. D-amino acid oxidase controls motoneuron degeneration through D-serine. Proc Natl Acad Sci U S A. 2012;109(2):627-632.
26. Boks MP, Rietkerk T, Van De Beek MH, Sommer IE, De Koning TJ, Kahn RS. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. Eur Neuropsychopharmacol. 2007;17(9):567-572.
27. Mechelli A, Prata D, Papagni SA, et al. Genetic vulnerability to psychosis and cortical function: epistatic effects between DAAO and G72 [published correction appears in Curr Pharm Des. 2013:19(4):806]. Curr Pharm Des. 2012;18(4):510-517.
28. Madeira C, FreitasME, Vargas-Lopes C, Wolosker H, Panizzutti R. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res. 2008;101(1-3):76-83.
29. Verrall L, Burnet PW, Betts JF, Harrison PJ. The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Mol Psychiatry. 2010;15(2):122-137.
30. MaekawaM, Okamura T, Kasai N, Hori Y, Summer KH, Konno R. D-amino-acid oxidase is involved in D-serine-induced nephrotoxicity. Chem Res Toxicol. 2005;18(11):1678-1682.
31. Almond SL, Fradley RL, Armstrong EJ, et al. Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia. Mol Cell Neurosci. 2006;32(4):324-334.
32. Rais R, Thomas AG, Wozniak K, et al. Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice. Drug Metab Dispos. 2012;40(11):2067-2073.
33. Adage T, Trillat AC, Quattropani A, et al. In vitro and in vivo pharmacological profile of AS057278, a selective D-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol. 2008;18(3):200-214.
34. Smith SM, Uslaner JM, Hutson PH. The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors. Open Med Chem J. 2010;4:3-9.
35. Javitt DC, Schoepp D, Kalivas PW, et al Translating glutamate: from pathophysiology to treatment. Sci Transl Med. 2011;3(102):102mr2.
36. Hashimoto K, Fujita Y, Horio M, et al. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry. 2009;65(12):1103-1106.
37. Caldinelli L, Molla G, Bracci L, et al. Effect of ligand binding on human D-amino acid oxidase. Protein Sci. 2010;19(8):1500-1512.
38. Van Den Berghe-Snorek S, StankovichMT. Thermodynamic control of D-amino acid oxidase by benzoate binding. J Biol Chem. 1985;260(6):3373-3379.
39. World Health Organization; International Programme on Chemical Safety. WHO-Concise International Chemical Assessment Document 26. Geneva, Switzerland: World Health Organization; 2000. www.inchem.org/documents/cicads/cicads/cicad26. htm#SubSectionNumber.11.1.1. Accessed September 12, 2013.
40. US Food and Drug Administration. GRAS (Generally Recognized As Safe) Food Ingredients: Benzoic Acid and Sodium Benzoate. Washington, DC: US Food and Drug Administration; 1972.
41. American Psychiatric Association. Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press; 1994.
42. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. ed 4. Washington, DC: American Psychiatric Press; 1994.
43. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
44. Andreasen NC. Scales for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1983.
45. Heinrichs DW, Hanlon TE, CarpenterWT Jr. The Quality of Life Scale. Schizophr Bull. 1984;10(3):388-398.
46. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health; 1976:217-222. US Dept of Health, Education, and Welfare publication (ADM) 76-338.
47. HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
48. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia. Biol Psychiatry. 2004;56(5):301-307.
49. ChenWJ, Liu SK, Chang CJ, Lien YJ, Chang YH, Hwu HG. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry. 1998;155(9):1214-1220.
50. Silver H, Feldman P, Bilker W, Gur RC. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry. 2003;160(10):1809-1816.
51. Wechsler D. Wechsler Memory Scale. 3rd ed. San Antonio, TX: Psychological Association; 1997.
52. Wechsler D. Wechsler Intelligence Scale for Children. 3rd ed. San Antonio, TX: Psychological Association; 1991.
53. Mayer JD, Salovey P, Caruso DR, Sitarenios G. Measuring emotional intelligence with the MSCEIT V2.0. Emotion. 2003;3(1):97-105.
54. MaWF, Tsai GE, Chang JP, Lane HY. Reliability and validity of three Chinese-version tasks of Mayer-Salovey-Caruso Emotional Intelligence Test. J Clin Nurs. 2010;19(17-18):2656-2658.
55. Lo CH, Tsai GE, Liao CH, et al. Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. Biol Psychol. 2010;83(2):79-83.
56. Lin CH, Tseng YL, Huang CL, Chang YC, Tsai GE, Lane HY. Synergistic effects of COMT and TPH2 on social cognition. Psychiatry. 2013;76(3):273-294.
57. Simpson GM, Angus J W S. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212(suppl):11-19.
58. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334(suppl):1-100.
59. Kern RS, Nuechterlein KH, Green MF, et al. The MATRICS Consensus Cognitive Battery, part 2. Am J Psychiatry. 2008;165(2):214-220.
60. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686-693.
61. Leucht S, Kane JM, KisslingW, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238.
62. Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology. 1995;13(4):335-345.
63. Bado P, Madeira C, Vargas-Lopes C, et al. Effects of low-dose D-serine on recognition and working memory inmice. Psychopharmacology (Berl). 2011;218(3):461-470.
64. Kantrowitz JT, Malhotra AK, Cornblatt B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res. 2010;121(1-3):125-130.
65. Kirkpatrick B, FentonWS, CarpenterWT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214-219.
66. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS. Methodological issues in negative symptom trials. Schizophr Bull. 2011;37(2):250-254.
67. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31(1):5-19.
68. Laruelle M, FrankleWG, Narendran R, Kegeles LS, Abi-Dargham A. Mechanism of action of antipsychotic drugs. Clin Ther. 2005;27(suppl A):S16-S24.
69. Khasnavis S, Pahan K. Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons. J Neuroimmune Pharmacol. 2012;7(2):424-435.
70. Food Standards Agency. Food Standards Agency issues revised advice on certain artificial colours. www.food.gov. uk/news/pressreleases/2007/sep/ colours. Accessed September 6, 2007.
71. McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community. Lancet. 2007;370(9598):1560-1567.